Literature DB >> 17123819

A scale to monitor progression and treatment of mitochondrial disease in children.

C Phoenix1, A M Schaefer, J L Elson, E Morava, M Bugiani, G Uziel, J A Smeitink, D M Turnbull, R McFarland.   

Abstract

Mitochondrial diseases affect all age groups, but those with childhood onset often seem to experience the greatest burden of disability. In some paediatric patients this can be explained by a cumulative disability acquired over many years. In others, additional factors, including the nature and severity of the molecular defect, must be considered. To date, no large-scale studies have attempted to document the natural history of paediatric mitochondrial disease. This is in part at least, because no assessment tool has been available to plot the temporal course of a disease with such a diverse clinical spectrum. This paper describes how a practical and semi-quantitative rating scale has been devised for children with mitochondrial disease, the Newcastle paediatric mitochondrial disease scale (NPMDS). The scale is multi-dimensional and reproducible, offering a tool through which mitochondrial disease progression can be objectively monitored. We anticipate that use of this tool will facilitate both longitudinal natural history studies and the assessment of future therapeutic interventions.

Entities:  

Mesh:

Year:  2006        PMID: 17123819     DOI: 10.1016/j.nmd.2006.08.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  22 in total

1.  Knowledge and awareness of mitochondrial diseases among physicians in the tertiary hospitals in Ghana.

Authors:  Eric A Mensah; Bismark Sarfo; Alfred E Yawson; Joshua Arthur; Augustine Ocloo
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Socio-emotional Problems in Children with CDG.

Authors:  K F E van de Loo; L van Dongen; M Mohamed; T Gardeitchik; T W Kouwenberg; S B Wortmann; R J T Rodenburg; D J Lefeber; E Morava; C M Verhaak
Journal:  JIMD Rep       Date:  2013-06-04

Review 3.  How can we treat mitochondrial encephalomyopathies? Approaches to therapy.

Authors:  Rita Horvath; Grainne Gorman; Patrick F Chinnery
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

4.  Toward a mtDNA locus-specific mutation database using the LOVD platform.

Authors:  Joanna L Elson; Mary G Sweeney; Vincent Procaccio; John W Yarham; Antonio Salas; Qing-Peng Kong; Francois H van der Westhuizen; Robert D S Pitceathly; David R Thorburn; Marie T Lott; Douglas C Wallace; Robert W Taylor; Robert McFarland
Journal:  Hum Mutat       Date:  2012-07-02       Impact factor: 4.878

5.  Succinate-CoA ligase deficiency due to mutations in SUCLA2 and SUCLG1: phenotype and genotype correlations in 71 patients.

Authors:  Rosalba Carrozzo; Daniela Verrigni; Magnhild Rasmussen; Rene de Coo; Hernan Amartino; Marzia Bianchi; Daniela Buhas; Samir Mesli; Karin Naess; Alfred Peter Born; Berit Woldseth; Paolo Prontera; Mustafa Batbayli; Kirstine Ravn; Fróði Joensen; Duccio M Cordelli; Filippo Maria Santorelli; Mar Tulinius; Niklas Darin; Morten Duno; Philippe Jouvencel; Alberto Burlina; Gabriela Stangoni; Enrico Bertini; Isabelle Redonnet-Vernhet; Flemming Wibrand; Carlo Dionisi-Vici; Johanna Uusimaa; Paivi Vieira; Andrés Nascimento Osorio; Robert McFarland; Robert W Taylor; Elisabeth Holme; Elsebet Ostergaard
Journal:  J Inherit Metab Dis       Date:  2015-10-16       Impact factor: 4.982

6.  Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation.

Authors:  Paul de Laat; Saskia Koene; Lambert P W J van den Heuvel; Richard J T Rodenburg; Mirian C H Janssen; Jan A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

Review 7.  Natural disease course and genotype-phenotype correlations in Complex I deficiency caused by nuclear gene defects: what we learned from 130 cases.

Authors:  S Koene; R J Rodenburg; M S van der Knaap; M A A P Willemsen; W Sperl; V Laugel; E Ostergaard; M Tarnopolsky; M A Martin; V Nesbitt; J Fletcher; S Edvardson; V Procaccio; A Slama; L P W J van den Heuvel; J A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2012-05-30       Impact factor: 4.982

8.  Nijmegen paediatric CDG rating scale: a novel tool to assess disease progression.

Authors:  Samira Achouitar; Miski Mohamed; Thatjana Gardeitchik; Saskia B Wortmann; Jolanta Sykut-Cegielska; Regina Ensenauer; Hélène Ogier de Baulny; Katrin Õunap; Diego Martinelli; Maaike de Vries; Robert McFarland; Dorus Kouwenberg; Miranda Theodore; Frits Wijburg; Stephanie Grünewald; Jaak Jaeken; Ron A Wevers; Leo Nijtmans; Joanna Elson; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2011-05-04       Impact factor: 4.982

9.  Successful use of albuterol in a patient with central core disease and mitochondrial dysfunction.

Authors:  L T W Schreuder; M W G Nijhuis-van der Sanden; A de Hair; G Peters; S Wortmann; L A Bok; E Morava
Journal:  J Inherit Metab Dis       Date:  2010-05-05       Impact factor: 4.982

10.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.